Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis
- Department of Radiation Oncology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, China
By Zhao Z, Ruan J, Fang M, Liu J and Liao G (2024). Front. Immunol. 15:1459693. doi: 10.3389/fimmu.2024.1459693
In the published article, there was a mistake in the affiliations of all authors. The affiliations of all authors were displayed as “Department of Radiation Oncology, Second Clinical Medicine Centre, Jinan University, Shenzhen, China.”
The correct affiliations of all authors is “Department of Radiation Oncology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, China.’’
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: chemotherapy, randomized controlled trials, cervical cancer, radiotherapy, immune checkpoint inhibitors
Citation: Zhao Z, Ruan J, Fang M, Liu J and Liao G (2024) Corrigendum: Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis. Front. Immunol. 15:1524791. doi: 10.3389/fimmu.2024.1524791
Received: 08 November 2024; Accepted: 14 November 2024;
Published: 20 November 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Zhao, Ruan, Fang, Liu and Liao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guixiang Liao, bGlhb2d1aXhpYW5nQDE2My5jb20=
†These authors have contributed equally to this work